Harvard Bioscience Faces Nasdaq Delisting Notice

Ticker: HBIO · Form: 8-K · Filed: Apr 10, 2025 · CIK: 1123494

Harvard Bioscience Inc 8-K Filing Summary
FieldDetail
CompanyHarvard Bioscience Inc (HBIO)
Form Type8-K
Filed DateApr 10, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, management-change, listing-standards

Related Tickers: HBIO

TL;DR

NASDAQ's coming for HBIO's listing, plus exec changes.

AI Summary

Harvard Bioscience, Inc. announced on April 10, 2025, that it received a notice from the Nasdaq Stock Market regarding its failure to meet continued listing requirements. The company is also addressing changes in its board of directors and executive officers, including the departure of certain officers and the election of new directors. Additionally, the filing includes information on compensatory arrangements for certain officers and other events.

Why It Matters

This filing indicates potential delisting from Nasdaq, which could significantly impact the company's stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — The company has received a notice of delisting from the Nasdaq Stock Market, indicating a significant risk to its continued public trading.

Key Players & Entities

  • Harvard Bioscience, Inc. (company) — Registrant
  • Nasdaq Stock Market (company) — Listing Exchange
  • April 10, 2025 (date) — Report Date

FAQ

What specific continued listing requirements did Harvard Bioscience fail to meet?

The filing states that Harvard Bioscience, Inc. received a notice from the Nasdaq Stock Market regarding its failure to satisfy a continued listing rule or standard, but the specific rule(s) are not detailed in the provided text.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is April 10, 2025.

What are the main categories of information covered in this 8-K filing?

The filing covers Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Other Events; and Financial Statements and Exhibits.

What is Harvard Bioscience, Inc.'s state of incorporation and fiscal year end?

Harvard Bioscience, Inc. is incorporated in Delaware and its fiscal year ends on December 31.

What is the business address and phone number for Harvard Bioscience, Inc.?

The business address is 84 October Hill Road, Holliston, MA 01746, and the business phone number is 508-893-8999.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 10, 2025 regarding HARVARD BIOSCIENCE INC (HBIO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.